Skip to main content

Advertisement

SpringerLink
Log in

Update on the Diagnosis and Management of Progressive Supranuclear Palsy

  • Neurology of Aging (K Marder, Section Editor)
  • Published:
Current Geriatrics Reports Aims and scope Submit manuscript

Abstract

Progressive supranuclear palsy (PSP) is an adult-onset neurodegenerative disease clinically characterized by a variable combination of symmetrical parkinsonism, early postural instability and falls, vertical supranuclear ophthalmoparesis, and cognitive decline. PSP is a disorder of 4-repeat tau protein aggregation, belonging to the family of tauopathies. A broad phenotypic variability has been recognized, and specific clinical diagnostic criteria are available. Several ancillary tests are helpful for diagnosis; however, there are no diagnostic biomarkers, and definite diagnosis still requires histopathological confirmation. Symptomatic management of PSP patients is limited, but recent advances in the understanding of its pathophysiology might lead us to disease-modifying treatments. A multidisciplinary approach is essential in managing the symptom complexity of a progressive condition such as PSP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance,•• Of major importance

  1. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol. 2002;1:359–69.

    Article  PubMed  Google Scholar 

  2. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354:1771–5.

    Article  CAS  PubMed  Google Scholar 

  3. Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124:1438–49.

  4. Steele J, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous system degeneration involving brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–59.

    Article  CAS  PubMed  Google Scholar 

  5. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol. 1997;41:277–81.

    Article  CAS  PubMed  Google Scholar 

  6. Oliva R, Tolosa E, Ezquerra M et al. Significant changes in the tau A0 and A3 alleles in progressive supranuclear palsy and imprved genotyping by silver detection. Arch. Neurol 1998; 55(8):1122–24

  7. Albers DS, Augood SJ, Park LC, et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem. 2000;74(2):878–81.

    Article  CAS  PubMed  Google Scholar 

  8. Pollock NJ, Mirra SS, Binder LI, et al. Filamentous aggregates in Pick’s disease, progressive supranuclear palsy, and Alzheimer’s disease share antigenic determinants with microtubule-associated protein tau. Lancet. 1986;2:1211.

    Article  CAS  PubMed  Google Scholar 

  9. Richardson JC, Steele JC, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. Trans Am Neurol Assoc 1963. p. 25-9.

  10. Duvoisin RC. Differential diagnosis of PSP. J Neural Transm Suppl. 1994;42:51–67.

    Article  CAS  PubMed  Google Scholar 

  11. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm Suppl. 1994;42:15–31.

    Article  CAS  PubMed  Google Scholar 

  12. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758–66. On this study of a cohort of 100 autopsy confirmed PSP patients the authors describe the clinical characteristics and natural history of the disease and propose different phenotypes according their predominance early features.

    Article  PubMed  Google Scholar 

  13. Williams D, De Silva R, Paviour D. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005;128:1247–58.

    Article  PubMed  Google Scholar 

  14. Riley DE, Fogt N, Leigh RJ. The syndrome of ‘pure akinesia’ and its relation to progressive supranuclear palsy. Neurology. 1994;44:1025–9.

    Article  CAS  PubMed  Google Scholar 

  15. Donker Kaat L, Boon AJ, Kamphorst W, et al. Frontal presentation in progressive supranuclear palsy. Neurology. 2007;69:723–9.

    Article  CAS  PubMed  Google Scholar 

  16. Golbe L. Progressive supranuclear palsy. Semin Neurol. 2014;34(2):151–9. An extended and educative overview of the disease is presented.

    Article  PubMed  Google Scholar 

  17. Golbe LI, Davis PH, Schoenberg BS, et al. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988;38:1031–4.

    Article  CAS  PubMed  Google Scholar 

  18. Ohman-Strickland P, Golbe L. A clinical rating scale for progressive supranuclear palsy. Brain. 2007;130:1552–65.

    Article  PubMed  Google Scholar 

  19. Rivaud-Pechoux S, Vidailhet M, Gallouedec G, et al. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2000;54:1029–32.

    Article  CAS  PubMed  Google Scholar 

  20. Quinn N. The “round the houses” sign in progressive supranuclear palsy. Ann Neurol. 1996;40:951.

    Article  CAS  PubMed  Google Scholar 

  21. Grandas F, Esteban A. Eyelid motor abnormalities in progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:33–41.

    Article  CAS  PubMed  Google Scholar 

  22. Brown RG, Lavomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 2010;133:2382–93.

    Article  PubMed  Google Scholar 

  23. Ghika J, Tennis M, Growdon J, et al. Environment-driven responses in progressive supranuclear palsy. J Neurol Sci. 1995;130:104–11.

    Article  CAS  PubMed  Google Scholar 

  24. Dubois B, Slachevsky A, Pillon B. “Applause sign” helps to discriminate PSP from FTD and PD. Neurology. 2005;64:2132–3.

    Article  CAS  PubMed  Google Scholar 

  25. Sixel-Döring F, Schweitzer M, Mollenhauer B, et al. Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med. 2009;10:407–15.

    Article  PubMed  Google Scholar 

  26. Valldeoriola F, Valls-Solé J, Tolosa E, et al. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord. 1995;10(5):550–5.

    Article  CAS  PubMed  Google Scholar 

  27. Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007;22:2235–41.

    Article  PubMed  Google Scholar 

  28. Imai H, Narabayashi H. Akinesia—concerning 2 cases of pure akinesia. Adv Neurol Sci (Tokyo). 1974;18:787–94.

    Google Scholar 

  29. Compta Y, Valldeoriola F, Tolosa E, et al. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord. 2007;22:1954–8.

    Article  PubMed  Google Scholar 

  30. Scaravilli T, Tolosa E, Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Mov Disord Suppl. 2005;20(12):S21–8.

    Article  Google Scholar 

  31. Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome; a cortical variant. Neuropathol Appl Neurobiol. 2014;40(2):149–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclaer palsy presenting as behavioural variant frontotemporal dementia. Neurocase. 2012;18:478–88.

    Article  PubMed  Google Scholar 

  33. Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol. 2008;21:688–92.

    Article  PubMed  Google Scholar 

  34. Joseph K, Ishizawa T, Tsuboi Y. A clinicopathological study of vascular progressive supranuclear palsy. A multi-infarct disorder presenting as progressive supranuclear palsy. Arch Neurol. 2002;59:1597–601.

    Article  Google Scholar 

  35. Morris H, Wood N, Lees A. Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgrad Med J. 1999;75:579–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13(3):273–8.

    Article  CAS  PubMed  Google Scholar 

  37. Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworths; 1987. p. 272–87.

    Google Scholar 

  38. Golbe L, Davis PH. Progressive supranuclear palsy. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. 2nd ed. Baltimore: William & Wilkins; 1993. p. 145–61.

    Google Scholar 

  39. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewskisyndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1–9.

    Article  CAS  PubMed  Google Scholar 

  40. Respondek G, Roeber S, Kretzschmar H. Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord. 2013;28:504–9.

    Article  PubMed  Google Scholar 

  41. Lang A. Clinical heterogeneity in progressive supranuclear palsy: challenges to diagnosis, pathogenesis and future therapies. Mov Disord. 2014;29:1707–9.

    Article  PubMed  Google Scholar 

  42. Hauw J-J, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015–9.

    Article  CAS  PubMed  Google Scholar 

  43. Rajput A, Rajput AH. Progressive supranuclear palsy: clinical features, pathophysiology and management. Drugs Aging. 2001;18:913–25.

    Article  CAS  PubMed  Google Scholar 

  44. Iwasaki Y, Yoshida M, Hashizume Y, et al. Widespread spinal cord involvement in progressive supranuclear palsy. Neuropathology. 2007;27:331–40.

    Article  PubMed  Google Scholar 

  45. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8:270–9.

    Article  PubMed  Google Scholar 

  46. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246:6–15.

    Article  Google Scholar 

  47. Paviour DC, Price SL, Stevens JM, et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2005;64:675–9.

    Article  CAS  PubMed  Google Scholar 

  48. Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14):1755–62.

    Article  Google Scholar 

  49. Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci. 2003;210:57.

    Article  PubMed  Google Scholar 

  50. Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005;64:2050.

    Article  CAS  PubMed  Google Scholar 

  51. Adachi M, Kawanami T, Ohshima H, et al. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci. 2004;3:125–32.

    Article  PubMed  Google Scholar 

  52. Cosottini M, Ceravolo R, Faggioni L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand. 2007;116:37–42.

    Article  CAS  PubMed  Google Scholar 

  53. Quattrone A, Nicoletti G, Messina D, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance. Radiology. 2008;246:214–22.

    Article  PubMed  Google Scholar 

  54. Hussl A, Mahlknecht P, Scherfler C, et al. Diagnostic accuracy of the magnetic resonance parkinsonism index and the midbrain to pontine area ratio to differentiate progressive supranuclear palsy from Parkinson’s disease and the Parkinson variant of multiple system atrophy. Mov Disord. 2010;25:2444–9.

    Article  PubMed  Google Scholar 

  55. Massey LA, Jäger HR, Paviour DC, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology. 2013;80(20):1856–61.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Stamelou M, Knake S, Oertel WH, et al. Magnetic resonance in progressive supranuclear palsy. J Neurol. 2011;258(4):549–58.

    Article  CAS  PubMed  Google Scholar 

  57. Holtbernd F, Eidelberg D. The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes. Semin Neurol. 2014;34:202–9. Recent advances in neuroimaging for the differential diagnosis of parkinsonian syndrome are discussed.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Tsukamoto K, Matsusue E, Kanasaki Y, et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson’s disease: evaluation by 3.0-T MR imaging. Neuroradiology. 2012;54(9):947–55.

    Article  PubMed  Google Scholar 

  59. Oh M, Kim JS, Kim JY, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple system atrophy. J Nucl Med. 2012;53(3):399–406.

    Article  CAS  PubMed  Google Scholar 

  60. Ghaemi M, Hilker R, Rudolf J, et al. Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73(5):517–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008;59(5):258–66.

    Article  PubMed  Google Scholar 

  62. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84(11):1288–95.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Villemagne V, Fodero-Tavoletti M, Masters C, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114–24. Review on latest advances on tau imaging and its usefulness as a diagnostic, prognostic, and progression biomarker of tauopathies.

    Article  PubMed  Google Scholar 

  64. Dani M, Edison P, Brooks DJ. Imaging biomarkers in tauopathies. Parkinsonism Relat Disord. 2016; S26eS28. This recent article reviews the challenges in developing selective tau ligands as biomarkers of tauopathies.

  65. Gironell A, Kulisevsky J, Roig C, et al. Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: a prospective study. Mov Disord. 2003;18(11):1273–9.

    Article  PubMed  Google Scholar 

  66. Bologna M, Agostino R, Gregori B, et al. Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy. Brain. 2009;132(Pt 2):502–10.

    PubMed  Google Scholar 

  67. Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology. 2004;63(3):504–9.

    Article  CAS  PubMed  Google Scholar 

  68. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol. 2007;64(11):1635–40.

    Article  PubMed  Google Scholar 

  69. Behnke S, Berg D, Naumann M. Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry. 2005;73(3):423–5.

    Article  Google Scholar 

  70. Magdalinou N, Lees J, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry. 2014;85:1065–75. Reviews the available evidence of several of the most promising cerebrospinal fluid candidate biomarkers in parkinsonian diosrders.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015;86(3):244–50.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445–52.

    Article  PubMed  Google Scholar 

  73. Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240–7. This study investigates the differences in CSF tau between Alzheimer’s disease and PSP.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Mondello S, Constantinescu R, Zetterberg H, et al. CSF α-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders. Parkinsonism Relat Disord. 2014;20(4):382–7.

    Article  PubMed  Google Scholar 

  75. Koros C, Stamelou M. Interventions in progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 22Suppl:S93-s95

  76. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16(4):338–46.

    Article  CAS  PubMed  Google Scholar 

  77. Poujois A, Vidailhet M, Trocello JM, et al. Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur J Neurol. 2007;14(9):1060–2.

    Article  CAS  PubMed  Google Scholar 

  78. Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73.

    Article  CAS  PubMed  Google Scholar 

  79. Progressive supranuclear palsy association; UK. Pathway of care for PSP a guide for health and social care professionals [Internet]. [Accessed 2 January 2016]; Available from: http://www.pspassociation.org.uk/for-professionals/resources-and-publications/

  80. Zampieri C, Di Fabio RP. Improvement of gaze control after balance and eye movement training in patients with progressive supranuclear palsy: a quasi-randomized controlled trial. Arch Phys Med Rehabil. 2009;90(2):263–70.

    Article  PubMed  Google Scholar 

  81. Stamelou M, de Silva R, Arias-Carrión, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010;133:1578–90.

    Article  PubMed  Google Scholar 

  82. Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranculear palsy. Mov Disord. 2014;29:470–8.

    Article  CAS  PubMed  Google Scholar 

  83. Stamelou M, Reuss A, Pilatus U, Magerkurth J, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23:942e949.

    Article  Google Scholar 

  84. Tsai RM, Boxer AL. Clinical trials: past, current, and future for atypical parkinsonian syndromes. Semin Neurol. 2014;34:225e234.

    Google Scholar 

Download references

Authors’ Contributions

All authors contributed equally to the preparation and review of the manuscript and approved the version submitted to the journal.

Author information

Authors and Affiliations

  1. Neurology Service, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Catalonia, Spain

    Alicia Garrido, Dolores Vilas & Eduardo Tolosa

  2. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Eduardo Tolosa

  3. Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

    Eduardo Tolosa

Authors
  1. Alicia Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dolores Vilas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo Tolosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Tolosa.

Ethics declarations

Conflict of Interest

Alicia Garrido, Dolores Vilas, and Eduardo Tolosa declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neurology of Aging

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garrido, A., Vilas, D. & Tolosa, E. Update on the Diagnosis and Management of Progressive Supranuclear Palsy. Curr Geri Rep 5, 85–94 (2016). https://doi.org/10.1007/s13670-016-0172-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13670-016-0172-y

Keywords

Search

Navigation